EUROPEAN JOURNAL OF HAEMATOLOGY
Scope & Guideline
Bridging Science and Practice in Blood Disorder Management
Introduction
Aims and Scopes
- Hematological Malignancies:
The journal covers a wide range of hematological malignancies, including acute myeloid leukemia, chronic lymphocytic leukemia, and multiple myeloma, focusing on innovative treatment strategies, clinical outcomes, and prognostic factors. - Transplantation and Cellular Therapies:
Research related to hematopoietic stem cell transplantation, including conditioning regimens, graft-versus-host disease, and CAR-T cell therapies, is a core area of interest, highlighting advancements and challenges in these fields. - Clinical Trials and Real-World Evidence:
The journal emphasizes the importance of clinical trials and real-world studies, exploring the efficacy and safety of new therapies, treatment patterns, and patient-reported outcomes in hematological diseases. - Genetic and Molecular Insights:
Studies investigating the genetic and molecular underpinnings of hematological disorders are featured, contributing to the understanding of disease mechanisms and the development of targeted therapies. - Quality of Life and Patient-Centered Care:
Research addressing health-related quality of life, psychosocial aspects of treatment, and patient-centered approaches in hematology is also a significant focus, reflecting the holistic view of patient care.
Trending and Emerging
- Immunotherapy and Targeted Treatments:
There is a notable increase in research related to immunotherapy, including CAR-T cell therapy and immune checkpoint inhibitors, highlighting their efficacy and safety in treating various hematological malignancies. - Real-World Evidence and Comparative Effectiveness:
Emerging studies focus on real-world evidence and comparative effectiveness research, assessing treatment outcomes in diverse patient populations and informing clinical decision-making. - Genomic and Biomarker Studies:
Research investigating genomic alterations and biomarkers for prognostication and treatment response is on the rise, reflecting a trend towards personalized medicine in hematology. - Quality of Life and Supportive Care Interventions:
An increasing emphasis on quality of life assessments, psychosocial interventions, and supportive care strategies for patients with hematological disorders indicates a broader focus on holistic patient care. - COVID-19 Impact on Hematology Patients:
The impact of COVID-19 on patients with hematological conditions has become a significant area of research, exploring infection rates, treatment adaptations, and outcomes in this vulnerable population.
Declining or Waning
- Traditional Chemotherapy Approaches:
Research focusing on traditional chemotherapy regimens for hematological malignancies appears to be declining, as newer, more targeted therapies and immunotherapies gain prominence in clinical practice. - Basic Laboratory Techniques:
Papers centered on basic laboratory techniques in hematology, such as routine blood tests and traditional cytogenetic analyses, have decreased as the field moves toward more advanced molecular diagnostics and personalized medicine. - Epidemiological Studies without Novel Insights:
Epidemiological studies that do not provide novel insights or advancements in understanding disease burden or treatment outcomes are becoming less frequent, as the focus shifts to studies with actionable results.
Similar Journals
ANNALS OF HEMATOLOGY
Fostering interdisciplinary dialogue in hematology and medicine.ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.
Journal of Blood Medicine
Empowering Research: Your Gateway to Innovations in HematologyThe Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.
Blood Cancer Journal
Fostering collaboration in the fight against blood cancer.Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.
Blood Science
Elevating Knowledge in Hematology and Transfusion MedicineBlood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.
Experimental Hematology & Oncology
Transforming Research into Breakthroughs in Hematology & OncologyExperimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.
Blood and Lymphatic Cancer-Targets and Therapy
Pioneering Insights into Blood and Lymphatic CancerBlood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.
INTERNATIONAL JOURNAL OF HEMATOLOGY
Championing Excellence in Hematology ResearchThe INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.
Hematology-American Society of Hematology Education Program
Advancing Hematology through Expert EducationHematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.
Therapeutic Advances in Hematology
Advancing hematology through innovative research.Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.
BONE MARROW TRANSPLANTATION
Empowering the Future of Bone Marrow Medicine.BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.